EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations

Kengo Yonezawa, Mayuko Hirata, Hiroaki Takano, Keisuke Kusudo, Sota Tomiyama, Lisa Harada, Kouta Suzuki, David J Nutt, Hiroyuki Uchida iD, Hideaki Tani iD

Psychiatry and Clinical Neurosciences · 2026-06 · 80 (6) · 438-458

DOI: 10.1111/pcn.70042 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 26.02.2026. Verfasst von Kengo Yonezawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Psilocybin, Hallucinogens, Neuroimaging, Mental Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review provides a comprehensive overview of psilocybin's history, recent clinical evidence, ongoing clinical trials, neuroimaging findings, and regulations. Historically used in spiritual and healing rituals, psilocybin was in the early 1970s subjected to strict legal restrictions that stalled research for decades. However, renewed scientific interest began in the 1990s, with studies demonstrating psilocybin's therapeutic potential for psychiatric disorders. Clinical trials have reported therapeutic effects of psilocybin in major depressive disorder (MDD), depressive symptoms associated with life‐threatening illnesses, and in some substance use disorders. Moreover, several phase III clinical trials of psilocybin for depression are currently underway, though trial data for obsessive‐compulsive disorder and bipolar depression are limited. Short‐term side effects are reportedly generally mild and transient, but long‐term effects still need further investigation. Neuroimaging research using magnetic resonance imaging and electroencephalography is still limited and focuses mainly on MDD. However, ongoing clinical trials include neuroimaging studies for psychiatric disorders beyond MDD, as well as positron emission tomography studies for MDD. Regulatory frameworks vary internationally. While many countries continue to classify psilocybin as a prohibited substance, use of psilocybin under controlled conditions is now permitted in Switzerland, parts of the United States, Canada, and Australia. Despite encouraging data, challenges remain, including the need for larger, blinded trials, standardized protocols, and clarification of long‐term efficacy and safety. Psilocybin represents a novel therapeutic approach in psychiatric treatment, warranting further rigorous scientific and regulatory research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinHallucinogensNeuroimagingMental DisordersClinical Trials as TopicHumans

Stichwörter der Autor:innen

law and ethicsneuroimagingpharmacopsychiatrypsilocybinpsychedelics

Substanzen

PsilocybinHallucinogens

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
  • Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.

ORCID-Profile: Hiroyuki Uchida, Hideaki Tani

Zitieren

APA

Yonezawa, K., Hirata, M., Takano, H., Kusudo, K., Tomiyama, S., Harada, L., Suzuki, K., Nutt, D. J., Uchida, H., & Tani, H. (2026). Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations. Psychiatry and Clinical Neurosciences, 80(6), 438-458. https://doi.org/10.1111/pcn.70042

Vancouver

Yonezawa K, Hirata M, Takano H, Kusudo K, Tomiyama S, Harada L, et al. Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations. Psychiatry and Clinical Neurosciences. 2026;80(6):438-458. doi:10.1111/pcn.70042

BibTeX
@article{Yonezawa2026,
  author = {Yonezawa, Kengo and Hirata, Mayuko and Takano, Hiroaki and Kusudo, Keisuke and Tomiyama, Sota and Harada, Lisa and Suzuki, Kouta and Nutt, David J and Uchida, Hiroyuki and Tani, Hideaki},
  title = {Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2026},
  volume = {80},
  number = {6},
  pages = {438--458},
  doi = {10.1111/pcn.70042}
}
Kostenlos starten →